DIABETES AND METABOLIC DISEASES

The presence of Novo Nordisk makes Medicon Valley’s diabetes research broad and deep, covering the entire field from molecular research to epidemiology.

Steno Diabetes Center is a diabetes research hospital and international teaching centre, owned by Novo Nordisk and private-publicly financed by Novo Nordisk and the Capital Region of Copenhagen.

Several Medicon Valley biotech companies are developing treatments based on proprietary technology platforms — these include Zealand Pharma (peptides for T2D), and 7TM Pharma (G-protein coupled receptors).